TNF Pharmaceuticals, Inc. (TNFA)
NASDAQ: TNFA · Real-Time Price · USD
0.1168
-0.0152 (-11.52%)
At close: Jul 25, 2025, 4:00 PM
0.1163
-0.0005 (-0.43%)
After-hours: Jul 25, 2025, 7:59 PM EDT

Company Description

TNF Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets.

The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease.

It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression.

The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2).

TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024.

The company was founded in 2014 and is headquartered in New York, New York.

TNF Pharmaceuticals, Inc.
TNF Pharmaceuticals logo
CountryUnited States
Founded2014
IndustryBiotechnology
SectorHealthcare
Employees2
CEOIan Rhodes CPA

Contact Details

Address:
1185 Avenue of the Americas, Suite 249
New York, New York 10036
United States
Phone856 848 8698
Websitetnfpharma.com

Stock Details

Ticker SymbolTNFA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001321834
CUSIP Number62856X201
ISIN NumberUS62856X2018
SIC Code2835

Key Executives

NamePosition
Dr. Mitchell Glass M.D.President, Chief Medical Officer and Director
Ian Rhodes CPAInterim Chief Financial Officer
Robert SchatzInvestor Relations Officer

Latest SEC Filings

DateTypeTitle
Jun 6, 20258-KCurrent Report
May 19, 2025DEFR14AFiling
May 15, 202510-QQuarterly Report
May 9, 2025PRER14AFiling
May 9, 20258-KCurrent Report
Apr 21, 2025ARSFiling
Apr 21, 2025DEF 14AOther definitive proxy statements
Apr 11, 2025PRE 14AOther preliminary proxy statements
Apr 11, 20258-KCurrent Report
Apr 11, 202510-KAnnual Report